Satoshi Miuma, Hisamitsu Miyaaki, Tatsuki Ichikawa, Toshihisa Matsuzaki, Takashi Goto, Yasuhiro Kamo, Masaya Shigeno, Naoyuki Hino, Keisuke Ario, Kenji Yanagi, Takuya Tsutsumi, Nobuyoshi Fukushima, Suguru Nakashiki, Kazufumi Yamasaki, Keisuke Hamasaki, Hidetaka Shibata, Kazuhiko Arima, Shinobu Yamamichi, Mio Yamashima, Kosuke Takahashi, Yasuhiko Nakao, Masanori Fukushima, Masafumi Haraguchi, Ryu Sasaki, Eisuke Ozawa, Naota Taura, Kazuhiko Nakao
BACKGROUND AND AIMS: Mortality after sustained virological response (SVR) with interferon-free direct-acting antiviral (IFN-free DAA) therapy is crucial for optimizing post-SVR patient care, but it remains unclear, especially regarding non-liver-related mortality. METHODS: Consecutive post-SVR patients from 14 institutions were stratified into three cohorts: A (without advanced fibrosis and without prior HCC), B (with advanced fibrosis and without prior HCC), and C (curative HCC treatment)...
March 2024: Journal of Medical Virology